Home / Products / Antibiotics / AEROFLOX-DZ
Click image to inspect pack details
Antibiotics Marketed by Aerochem Neutron

AEROFLOX-DZ

Formulation Code AC-477
Commercial Status Active Product Information Available

Product Overview & Formulation Profile

Composition: Ofloxacin IP 200mg + Ornidazole 500 mg (tablets). The rationale for the combination is complementary action: Ofloxacin (fluoroquinolone antibacterial) and Ornidazole (nitroimidazole antimicrobial).

Ofloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV. Ornidazole is a nitroimidazole active against susceptible anaerobic bacteria and protozoa such as Entamoeba histolytica and Giardia lamblia.

AEROFLOX-DZ is a prescription medicine from Aerochem Neutron's antibiotic range, for use on the prescription of a registered medical practitioner..

Composition & Formulation Details

·       Contains Ofloxacin IP 200mg + Ornidazole 500 mg

·       Ofloxacin — a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV

·       Ornidazole — a nitroimidazole active against susceptible anaerobic bacteria and protozoa such as Entamoeba histolytica and Giardia lamblia

·       Presented as tablets

Prescription-only medicine

·       Acute and chronic infective diarrhoea and dysentery of mixed bacterial/protozoal origin

·       Gastrointestinal infections, including amoebiasis

·       Enteric fever, where the combination is clinically appropriate

·       Other indications as per the approved prescribing information

·       Note: indications reflect established uses of the individual molecules; confirm against the CDSCO-approved label for this fixed-dose combination


Safety

·       Contraindicated in patients with known hypersensitivity to any component.

·       Fluoroquinolones carry warnings for tendinitis and tendon rupture, peripheral neuropathy, CNS effects, QT prolongation, dysglycaemia and aortic aneurysm risk, and can worsen myasthenia gravis; reserve for situations where they are clearly appropriate and avoid in pregnancy and in children unless benefits outweigh risks.

·       Nitroimidazoles may cause metallic taste, gastrointestinal upset and, rarely, peripheral neuropathy or seizures; avoid alcohol during and shortly after therapy and use caution in the first trimester of pregnancy.

·       Refer to the full prescribing information for all contraindications and interactions.

Clinical Rationale: The mechanisms and labelled uses of ofloxacin described here follow the US prescribing information (DailyMed); the EMA 2018 fluoroquinolone review restricted these agents because of disabling and potentially long-lasting adverse effects, which is why use should be limited to cases where they are clearly appropriate; antibiotic choice should follow local resistance data and the WHO AWaRe antibiotic book. Evidence summary for Ornidazole: reference verification pending. Use of the combination should follow the CDSCO-approved label for this fixed-dose combination.

References 

·       DailyMed (US NLM) prescribing information – ofloxacin: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=OFLOXACIN

·       EMA – Quinolone and fluoroquinolone medicines referral (2018): https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products

·       WHO AWaRe (Access, Watch, Reserve) antibiotic book (2022): https://www.who.int/publications/i/item/9789240062382

·       Reference verification pending for: Ornidazole

Professional Product Enquiries

Verified product information, formulation specifications, and commercial supply pathways for registered healthcare professionals, institutions, and trade partners.

Product Information

Review verified active composition, strength, dosage form, and packaging details on this page.

View Specifications

Healthcare Professional Enquiry

Request formulation literature, technical specifications, or product communication from our commercial team.

Submit Product Enquiry

Commercial Supply Enquiry

Connect regarding institutional supply requirements, trade distribution, or third-party contract manufacturing.

Commercial Enquiry

Professional Product Information

This product information is intended for registered healthcare professionals, medical practitioners, and authorized distribution partners. Product manufacturing is coordinated through eligible facility partners under applicable licences.

Product Enquiry

Request Formulation Details

Request information about AEROFLOX-DZ for professional use.

Please enter the numeric sum to verify you are a human visitor.
Approved Resources

Distributor Media

Product Image - AEROFLOX-DZ
Product Image

AEROFLOX-DZ — Product Image

Therapeutic Alternatives

Related Formulations

SULTAVIN Formulation
AEROCLAV -625 Formulation
AEROFLOX 200 Formulation
A.G 250 Formulation
Product Information

Need specifications for this formulation?

Request verified product information for professional use, or send a separate business enquiry for manufacturing or partnership discussions.

WhatsApp: +91 9512047000